临床儿科杂志 ›› 2018, Vol. 36 ›› Issue (4): 299-.doi: 10.3969/j.issn.1000-3606.2018.04.015

• 循证医学 • 上一篇    下一篇

儿童万古霉素血药谷浓度与临床结局相关性的 meta 分析

曹璐 1,2, 薛学财 1, 文爱东 2, 于锋 1   

  1. 1.中国药科大学基础医学与临床药学学院(江苏南京 210009);2.第四军医大学西京医院药剂科 (陕西西安 710032)
  • 收稿日期:2018-04-15 出版日期:2018-04-15 发布日期:2018-04-15
  • 通讯作者: 于锋 E-mail: yufengcpu@163.com

Meta-analysis of the correlation between the blood trough concentration of vancomycin and the clinical outcome in children

 CAO Lu1,2,  XUE Xuecai1, WEN Aidong2, YU Feng1   

  1. 1.School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, Jiangsu, China; 2. Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China
  • Received:2018-04-15 Online:2018-04-15 Published:2018-04-15

摘要: 目的 运用meta分析方法评价儿童万古霉素血药谷浓度与临床疗效及安全性的关系。 方法 全面检索 PubMed、Elsevier、Web of Science、Medline、Clinicaltrials.gov、Cochrane Library、CBM、CNKI及万方等数据库,收集万古 霉素用于儿童感染性疾病治疗的研究资料,用Cochrane系统评价方法筛选文献,评价纳入文献的质量,并提取纳入特征信 息,进行meta分析。结果评估包括临床有效率,肾、肝、耳毒性发生率及病死率。结果 共纳入20篇文献,包括3 204例使 用万古霉素的儿童。Meta分析结果显示,与万古霉素谷浓度≤10 μg/mL相比,谷浓度>10 μg/mL患儿的临床有效率更 高(OR=2.59,95% CI:1.33~5.05, P<0.05),肾毒性发生率更高(OR=3.63,95% CI:2.31~5.7, P<0.05),耳毒性发生 率更高(OR =2.43,95% CI:1.25~4.72, P<0.05),病死率更高(OR=2.41,95% CI:1.13~5.14, P<0.05);万古霉素谷 浓度与肝毒性不相关。亚组分析结果显示,与万古霉素谷浓度10~15 μg/mL相比,谷浓度>15 μg/mL 的患儿肾不良反应 发生率更高(OR=2.54,95% CI:1.59~4.08; P<0.05),临床有效率差异无统计学意义(OR=0.59,95% CI:0.17~2.03; P>0.05)。 结论 万古霉素血药谷浓度≤10 μg/mL,临床治疗效果欠佳,不良反应发生率较低;谷浓度>15 μg/mL,不良 反应发生率较高,临床治疗效果与10~15 μg/mL相当,故谷浓度在10~15 μg/mL比较合适。

Abstract:  Objective A meta-analysis method was used to evaluate the relationship between serum vancomycin trough concentration and its clinical efficacy and safety in children. Method Database of PubMed, ELSEVIER, Web of Science, Medline, Clinicaltrials.gov, Cochrane Library, CBM, CNKI, and Wanfang were searched. And research data of vancomycin in the treatment of infective diseases in children were collected. Cochrane system was used to evaluate the quality of the included literature, and the feature information was extracted and meta-analysis was carried out. Outcomes include clinical efficiency, the incidence of renal toxicity, liver toxicity and ototoxicity, and the fatality rate. Results A total of 20 articles were included, containing 3204 children treated with vancomycin. The results of meta-analysis showed that there were higher clinical efficiency (OR=2.59, 95% CI:1.33~5.05, P<0.05), higher incidence of renal toxicity (OR=3.63, 95% CI:2.31~5.7, P<0.05), higher incidence of ototoxicity (OR=2.43, 95% CI:1.25~4.72, P<0.05), and higher mortality (OR=2.41, 95% CI:1.13~5.14, P<0.05) in the trough concentration>10 μg/mL group than in vancomycin trough concentrations ≤10 μg/mL. The vancomycin trough concentrations were not related to hepatotoxicity. Subgroup analysis showed that children with trough concentration >15 μg/mL had higher renal adverse reaction (OR=2.54, 95% CI:1.59~4.08, P<0.05) than those with vancomycin trough concentrations at 10~15 g/mL, and there was no significant difference in clinical efficacy (OR=0.59, 95% CI:0.17~2.03, P>0.05). Conclusion Vancomycin trough concentration ≤10 μg/mL has poor clinical efficacy with low incidence rate of adverse reaction. Trough concentration >15 μg/ mL has a higher incidence of adverse reaction, and the effect of clinical treatment is equal to that of trough concentration 10~15 g/mL. Therefore, the trough concentration of 10~15 μg/mL is suitable.